Autophagy is a multistep catabolic process through which misfolded, aggregated or mutated proteins and damaged organelles are internalized in membrane vesicles called autophagosomes and ultimately fused to lysosomes for degradation of sequestered components. The multi-step nature of the process offers multiple regulation points prone to be deregulated and cause different human disease, but also offers multiple targetable points for designing therapeutic strategies. Cancer cells have evolved to use autophagy as an adaptive mechanism to survive under extremely stressful conditions within tumor microenvironment, but also to increase invasiveness and resistance to anti-cancer drugs such as chemotherapy. This review collects all clinical evidences of autophagy deregulation during cholangiocarcinogenesis together with all pre-clinical reports evaluating compounds that modulate autophagy to induce cholangiocarcinoma (CCA) cell death. Altogether, experimental data suggests an impairment of autophagy during initial steps of CCA development and increased expression of autophagy markers on established tumors and in invasive phenotypes. Pre-clinical efficacy of autophagy modulators promoting CCA cell death, reducing invasiveness capacity and resensitizing CCA cells to chemotherapy open novel therapeutic avenues to design more specific and efficient strategies to treat this aggressive cancer limited efficacy, showing high chemoresistance and death rates [2,11,12]. The only curative treatment is radical surgical resection and liver transplantation, which are limited to cure locally restricted disease [13,14]. However, most of newly diagnosed patients present with advanced or even metastatic stages of disease and chemotherapy is the only treatment option. Among all chemotherapeutic regimes available, only the combination of gemcitabine and cisplatin exerts some growth-inhibiting effects at advanced stages of the disease [15,16].
Introduction
Cholangiocarcinoma (CCA) is a very aggressive epithelial cell malignancy arising from varying locations within the biliary tree, a complex network of ducts that deliver bile to the gallbladder and to the intestine [1] . CCA originates from cholangiocytes located at any portion of the biliary tree and represents the most common biliary duct malignancy and the second most frequent cancer of the liver after Hepatocellular Carcinoma (HCC), accounting for 10-20% of all primary liver cancers [2] [3] [4] .
The classification of CCA has been a matter of debate during the past decades and depending on different aspects of these tumors, several classifications have been proposed. Based on the anatomy of the biliary tract and the different origin of the tumor, CCA is classified into three different types: intrahepatic cholangiocarcinoma (iCCA), which originates from the biliary tree within the liver proximal to the second-order bile ducts, and extrahepatic cholangiocarcinoma (eCCA), which originates outside the liver parenchyma. eCCA is further subdivided into perihilar cholangiocarcinoma (pCCA), arising between the second-order bile ducts and the insertion of the cystic duct into the common bile duct, and distal cholangiocarcinoma (dCCA), arising between the insertion of the cystic duct and the ampulla of Vater [2, 5, 6] . Although this anatomical classification is the most widely used, other factors such as tumor growth pattern (mass-forming, periductal infiltrating or intraductal) and the cell of origin (cholangiocytes, peribiliary glands, hepatic progenitor cells or hepatocytes) offer alternative classification that may be more useful in specific clinical settings [7] [8] [9] [10] .
CCA is a very deadly cancer which at an early stage remain asymptomatic and is normally diagnosed at advanced stages and in elderly, where therapeutic options are reduced and with with UV radiation resistance-associated gene protein (UVRAG or p63) and activating molecule in BECN1-regulated autophagy protein 1 (Ambra1), depending on the subcellular localization of the complex [37] . Beclin1 (Bcl-2 homology (BH)-3domain only protein) is initially complexed with and inhibited by anti-apoptotic protein Bcl-2, and upon different stimuli, this complex is disrupted and Beclin1 released to initiate autophagy. ULK1 phosphorylates Beclin1, which acts as an overall scaffold for the PI3K complex facilitating localization of autophagic proteins into the phagophore [37] . This initial activation is coordinated by different inputs from the mechanistic target of rapamycin complex 1 (mTORC1) and AMP-activated protein kinase (AMPK). Under physiological non-stressed conditions, mTORC1 phosphorylates ULK1/2, keeping ULK complex inactive. When nutrient, energy, growth factors or other stress conditions affect the cells, mTORC1 is suppressed and therefore ULK1 complex is dephosphorylated and activated. Activated ULK complex translocates to phagophore and induces vesicle nucleation by activating PI3K-Beclin1 complex [37] . These events lead to autophagosome formation following the extension and closure of the mature autophagosome. Two ubiquitin-like conjugation systems are main regulators for maturation, enlongation and closure of the autophagosome membrane. On one side, ATG7 and ATG10 conjugate ATG5 to ATG12. ATG5-ATG12 forms a complex with ATG16L1. The ATG5-ATG12-ATG16L1 large multimeric (E3-like) complex gets anchored on the emerging autophagosomal membranes and recruits members of the microtubule-associated protein 1 light chain 3 (LC3) and GABARAP families to the autophagosome. On the other side, ATG7 and ATG3 conjugate the soluble form of LC3 (LC3-1) to phosphatidylethanolamine (PE), forming the lipidated form of LC3-I (LC3-II) on the surface of the emerging autophagosome guided by the ATG5-ATG12-ATG16L1 complex, that locates LC3-II on membrane to identify it as autophagic membrane and recruit more autophagic cargo through specific receptors [38] . LC3-II) is often used in research as a marker for autophagy progression, since it localizes to both the inner and outer membranes of phagophores and autophagosomes and migrates faster than LC3-I on gel electrophoresis, allowing to evaluate the ratio of lapidated LC3 to reflect the number of autophagosomes formed. The adaptor protein sequestosome 1 (p62) targets specific substrates to autophagosomes and is are degraded along with other cargo proteins, therefore it is normally used as a measure of autophagic flux [39] .
A this point of the process, autophagosome is formed and is ready to internalize autophagic cargo and transport them on microtubules to the perinuclear region where lysosomes are present. Upon maturation, autophagosomes go into the last step in this catabolic process, the fusion of autophagosomes with lysosomes to form the autophagosome, process that is regulated by three sets of protein families: the Rab GTPasas (Rab7 in autophagy), HOPS (homotypic fusion and protein sorting-tethering complex) and the soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) proteins [40] . HOPS is a conserved protein complex consisting of vacuolar protein sorting 11 (Vps11), Vps16, Vps18, Vps33, Vps39, and Vps41 and mediates autophagosome-lysosome fusion through interaction with SNARE syntaxin 17 [41] . In this final step, UVRAG, which plays an important role facilitating Vps34 activation during initial steps of autophagy, shows a relevant role regulating autophagosome maturation via Beclin1 independent manner. UVRAG recruits class C vacuolar protein soring (C-Vps) complex to autophagosomes, where UVRAG-C-Vps interaction stimulates Rab7-GTPase activity that results in autophagosome fusion to lysosomes [42] . Lastly, in the degradation phase, autophagic cargo is degraded under the low pH of autophagolysosome that activates specific lysosomal hydrolases, recycling degraded material to be used to fuel growth of the cell.
Autophagy was initially defined as a pro-survival cellular mechanism due to its role in maintaining homeostasis under stressful conditions. Deregulation of autophagy has been related with multiple human diseases, including cancer [19], where it has been shown to act as a tumor promoter or tumor suppressor depending on the cell context [21] , and therapeutic modulation of autophagy has shown promising therapeutic potential [20] [21] [22] [23] [24] [25] .
Schematic overview of the autophagy molecular pathway and target steps of its modulation. Upon nutrient or energy deprivation AMPK is activated, leading to mTORC1 inhibition and autophagy induction. Stress conditions activate the UPR response mediated by PERK and IRE-1, which leads to the activation of autophagy. ULK complex consists in ULK1, ULK2, FIP200 and ATG13. The PI3K-Beclin1 complex consists in VPS34, VPS15, Beclin1 and ATG14, or VPS34, Beclin1, UVRAG and Ambra1. These complexes mediate the generation of lipidated LC3 (LC3-II) and its incorporation into phagophore membrane. The elongation of the phagophore ultimately closes and forms the autophagosome, which internalizes autophagosome cargo and fuses with lysosomes for cargo degradation and nutrient recycling. Current approaches to modulate autophagy in CCA target different steps. Autophagy inhibitors focus on inhibiting the last step, interfering with lysosome fusion or function, but other compounds target mTORC1 or other initiation steps. Autophagy activators act through targeting initial steps of autophagy, mTOR inhibition or ER stress induced autophagy
Autophagy as a tumor suppressor
Deficiencies in autophagy lead to the accumulation of impaired macromolecules and organelles that disrupt cell homeostasis and cause DNA damage and chromatin instability, key factors in the accumulation of oncogenic mutations. During the initial stages of malignant transformation, autophagy exerts a cytoprotective role mainly acting as tumor suppressor, lessening the effects of metabolic stress and genome instability that cause tumor initiation [43, 44] . Mostly, inhibition of autophagy in cancer cells lies in the over-activation of the PI3K-Akt-mTORC1 pathway, which induces survival and proliferation [45] . Accordingly, several tumor suppressor genes such as PTEN [46], LKB1, AMPK [47] or TSC [48] are promoters of autophagy. Some of the most important evidences demonstrating the role of autophagy as a tumor suppressor come from studies performed with Beclin1 [49]. Mice with genetic deletion of Beclin1 show higher incidence of lymphoma, lung cancer and liver cancer [28] . In addition, mono-allelic deletions of Beclin1 gene have been described in 40-75% of human cancers of the breast, ovary and prostate [50] . Consonant with these results, silencing of ATG5 results in the accumulation of p62 protein aggregates, defective mitochondria and poorly folded proteins, events that induce ROS (reactive oxygen species) production. Increase in ROS favors the appearance of potentially oncogenic mutations, and autophagy prevents malignant transformation by clearing accumulated p62 and limiting chromosome instability [43, 51, 52] .
Autophagy as a tumor promoter
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Activation of autophagy in established growing tumor cells is a common event among different types of cancers due to the extreme environmental conditions typical of the progressive tumor environment, such as lack of oxygen [53], limited nutrients [54] and increasing energy demand by sustained high metabolic rate [55] . Under these circumstances, autophagy appears as an adaptive cellular response that allows tumor cells to survive under severe conditions. RAS-mutated cells are highly dependent on autophagy and are defined as "addicted to autophagy". Oncogenic mutations in RAS are found in about 30% of human cancers and are tumors with high proliferative and metastatic potential [56, 57] . Several studies have described that these cells depend on autophagy activation to maintain oxidative metabolism and glycolysis underpinning growth, survival, invasion and metastasis [58, 59] . Autophagy is also presented as a protective strategy for tumor cells to evade the effect of various therapies and promote chemoresistance and tumor survival [60] [61] [62] [63] . Drugs such as tamoxifen [64], temozolamide [65], resveratrol [66] or arsenic trioxide induce protective autophagy in cancer cells of the breast, prostate, colon and malignant glioma [67] . Radiotherapy has also shown induction of protective autophagy [68] . In many cases, the activation of autophagy has been linked to the development of resistance to these treatments. In this line, it has been described that the combination of autophagy inhibitors with chemotherapy, radiotherapy, tyrosine kinase receptor inhibitors or hormone therapy sensitizes cells to these treatments [67, 68] .
CHOLANGIOCARCINOMA GENETIC AND EPIGENETIC ALTERATIONS AND AUTOPHAGY
CCA is a very heterogeneous group of malignancies highly influenced by different risk factors and genetic and epigenetic alterations [69] . Surgery, chemotherapy and locoregional therapy are the only approved therapies for CCA, although less than one-third of the patients have been classified as having a resectable tumor at the time of diagnosis. Tumor resection is usually followed by adjuvant chemotherapy using gemcitabine, cisplatin or 5-FU (5-fluorouracil), which nevertheless does not prevent the high rates of relapse and resistance. For patients presenting with unresectable or metastatic CCA, systemic chemotherapy remains the mainstay palliative treatment modality, and only gemcitabine plus cisplatin combination has offered limited advantages [15, 16] , usually followed by a fluoropyrimidine-based regimen when gemcitabine-based treatment fails [69] . The identification of genetic and epigenetic alterations and the increased knowledge about molecular pathophysiological mechanisms governing cholangiocarcinogenesis, tumor recurrence, resistance and metastasis, has allowed the development of more specific therapies, although clinical results evaluating specific molecular agents demonstrate no or only very modest survival benefits of the agents tested [4,5,70].
Whole genome analyses identified two distinct genomic classes of iCCA: an inflammatory class with predominant activation of inflammatory pathways, and a second proliferative class with predominant activation of oncogenes that correlate with worse patient outcome [71]. Next generation sequencing analysis revealed that the majority of CCAs showed a driver gene mutation, although tumors from different sites (iCCA versus pCCA and dCCA) have different genetic profiles. For example, RAS appears frequently mutated in CCA, with a higher prevalence in dCCA [72] . Exom sequencing analysis identified a unique subtype of CCA without RAS mutation and/or FGFR2 fusion genes [73] . Epigenomic studies have revealed that epigenetic modification such as DNA hypermethylation, histone modifications and microRNAs deeply affect CCA development [74] . All these data support the complexity of this type of cancer and the low efficacy of current diagnostic methods and therapies and deeper research into mechanism leading to CCA development will help to support the development of novel treatments that could improve therapeutic outcome based on proper patient classification.
Chronic inflammation, partial bile flow obstruction (i.e. cholestasis), and bile duct injury are recognized to be major features for malignant transformation [75] . Upon chronic inflammation, both cholangiocytes and immune cells secrete pro-inflammatory cytokines such as IL-6, endotoxins or TNF-α. Sustained IL-6 production acts as key player in hepatobiliary inflammation and cancer development, promoting mitogenic responses and cell survival [76] . Additionally, IL-6 can increase nitric oxide synthase (iNOS)-mediated nitric oxide production resulting in DNA damage [77] and cyclic oxygenase (COX)-2-mediated prostaglandin secretion that results in cell growth, anti-apoptosis and angiogenesis [78] . Autophagy plays a relevant role in inflammation, although understanding of this interconnection is still incomplete [79] . Many of the signaling pathways that control inflammation during tumorigenesis are also known regulators of autophagy. For example, in lung cancer cells exposed to arsenic, oncogenic transformation correlates with sustained upregulation of IL6 and reduced autophagy [80] and IL-6-dependent transformation requires inhibition of a Beclin1-Bcl2 complex, which is dependent on STAT3 signaling. Moreover, enhancement of autophagy via Beclin1 overexpression is sufficient to block IL-6 mediated transformation [80] . This correlation between IL-6 mediated carcinogenesis and autophagy may represent an interesting and promising approach to treat iCCA with an inflammatory component. Additionally, there are a large number of studies that relate different pro-inflammatory pathways with ER stress and autophagy [79,81,82].
To date, different genes have been related to cholangiocarcinogenesis. Activating KRAS mutations are frequently detected in all subtypes of CCA and can be found in up to 40% of CCA, with major prevalence in dCCA [72], while BRAF mutations contribute with RAS to CCA development [83, 84] . Moreover, KRAS mutation collaborates with p53 deletion to cause iCCA [83] and it has been shown that p53 status determines the role of autophagy in pancreatic tumor development [85] . Interestingly, KRAS and BRAF-driven pancreatic and lung cancers have been shown to be addicted to autophagy, showing elevated levels of autophagy-related proteins. Autophagy inhibition with chloroquine (CQ) in these cancers enhances chemotherapy efficacy [56,86-89]. Nonetheless, in mice containing oncogenic KRAS and lacking p53, inhibition of autophagy no longer blocks tumor progression, instead accelerates tumor onset and enriches anabolic pathways that can fuel tumor growth [83] . Moreover, iCCA cell lines with mutated p53, which alterations have also been widely described in CCA [90] and KRAS have elevated autophagy compared with normal iCCA cells, and CQ inhibited growth of these cells [91], addressing the need to clearly define whether autophagy is a feature of all iCCA or if only applies just for KRAS mutated variants. No specific RAS inhibitors have been developed so far and targeted therapies aiming to modulate KRAS downstream pathways such as MEK1/2 inhibitor selumetinib are in development for CCA, pointing to the potential combination with autophagy inhibitors to improve their therapeutic potential [4, 92] . Alterations in c-MET, which overactivation leads to activation of MAPK, PI3K/Akt and STAT pathways, correlates with high grade, invasiveness and poor prognosis in CCA [93,94], and its inhibition promoted autophagy in lung cancer cells [95], further linking c-MET mediated autophagy inhibition in carcinogenesis. Gain of function mutation in ERBB2 and EGFR genes correlates with malignancy in human cholangiocytes, cancer progression and poor survival [96,97], and treatment with tyrosine kinase inhibitors induced protective autophagy in different cancer types [98], suggesting that the combination with autophagy inhibitors could increase the efficacy of these compounds. Similarly, FGFR2 fusion genes that result in altered cell morphology and increased cell proliferation have been described in CCA [99] . It has been shown that FGFR alterations suppress autophagy and genetic or pharmacological FGFR inhibition induces protective autophagy in lung and breast cancer, therefore inhibition of autophagy increases anticancer efficacy of FGFR inhibitors [100,101]. There are currently FGFR inhibitors in clinical development for CCA, opening the possibility to evaluate the combination of these inhibitors with autophagy modulators to increase efficacy. Loss of SMAD4 is also frequently observed in CCA in the distal common bile duct [102] and it has also been shown to render pancreatic cancer radioresistance through promotion of autophagy [103], therefore combination with autophagy inhibitors also could potentially apply to these mutated tumors. Adenomatous Polyposis Coli (APC) is an additional tumor suppressor commonly mutated in CCA and may be responsible for the early stages of carcinogenesis [104], stages where dysfunctional autophagy has also been detected in clinical samples [105] and in xenografts during tumor formation [106].
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Additionally, it has been proposed that epigenetic changes such as histone modifications, DNA methylation and non-coding RNAs, which play a very relevant role in the pathophysiology of CCA [107], are also regulators of autophagy [108] . Overexpression of histone deacetylase 6 (HDAC6) was reported in CCA, promoting the shortening of the primary cilium and inducing hyperproliferation. HDAC6 inhibition restores ciliary expression and decreases tumor growth in CCA [109,110], a mechanism that has been shown to be mediated by autophagy inhibition in colorectal cancer, multiple myeloma and neuroblastoma [111] . Other HDACs, such as HDAC1, has been found overexpressed in CCA and correlates with malignant behavior and poor iCCA prognosis [112] . Histone methylations also control autophagic flux and it has been proposed that histone methylation keeps the brakes on autophagy [113] . DNA methylation mediated silencing of tumor suppressor genes is oftenly seen in CCA. Frequent mutations in both DNA methylation IDH1 and IDH2 have been reported in 10% of iCCA, which are associated with hypermethylation of CpG shore, resulting in an altered state in the cellular process of differentiation [114, 115] . Several reports highlight the link between autophagy inhibition and histone methylation [108], [113], proposing autophagy inhibition as a target for treating IDH mutant gliomas [116] . A number of microRNAs (e.g., miR-141, miR-200b, miR-21, miR-29b among others) have been described to be either up or downregulated in CCA cell lines, and their predicted targets were found to be associated with cell growth, apoptosis and response to chemotherapy in CCA cell lines [117, 118] . MicroRNAs are also involved in regulating autophagy in cancer, and different autophagy related proteins have been described as miRNAs targets, such as ULK2, Beclin1, LC3, ATG4 or ATG9 [119,120]. Moreover, miR-124 has been described to induce cytotoxic autophagy in CCA through EZH2-STAT3 pathway in vitro and in vivo [29] .
AUTOPHAGY MODULATION IN CHOLANGIOCARCINOMA
Although the knowledge about the role of autophagy in cholangiocarcinogenesis and specific pathologic and potential therapeutic roles of its modulation are still poorly understood, several reports have identified autophagy related markers with prognostic significance, underlining the relevance of this process in CCA and offering novel therapeutic strategies. Similar to pancreatic cancer, CCA follows a carcinogenic development in which a precursor lesion, a biliary intraepithelial neoplasia (BilIN), is developed. The study of the expression levels of LC3, Beclin1 and p62, along with p53 and KRAS status on clinical BilIN samples and compared with normal bile duct and peribiliary gland, revealed that autophagy deregulation may occur at an early stage of development of CCA [105]. Expression of LC3 and p62 was high in BilIN 1-2 stages compared with normal cholangiocytes, and all three LC3, Beclin1 and p62 were higher in invasive carcinoma compared with non-tumoral tissue. No significant correlation between KRAS and expression of autophagy markers in BilIN 1-2 stages was observed. Accumulation of autophagic proteins is indicative of deregulated autophagy, and autophagy impairment accumulates these proteins in the cytoplasm, which could correlate with the tumor suppressor role of autophagy during initial stages of cancer development. In preclinical studies, autophagy was detected in human CCA cell lines under starvation conditions and during tumor formation in xenograft models. Furthermore, genetic or pharmacological inhibition of autophagy hampered proliferation and increased apoptosis during nutrient starvation, sensitizing iCCA cells to chemotherapeutic agent induced cell death [106] . In addition, iCCA clinical samples showed higher autophagic vacuoles and higher expression levels of Atg5 and Beclin1 compared with normal bile epithelium [106], which could correlate with tumor promoter role of autophagy in established growing tumors.
Epithelial to Mesenchymal Transition (EMT) is considered to be a major driver of cancer exacerbation, promoting tumor progression, metastasis and drug resistance [121, 122] . The link between EMT and autophagy has been amply demonstrated, since main pathways regulating autophagy have a dramatic impact on EMT, such as PI3K/AKT/mTOR, Beclin1, p53 and JAK/STAT signaling pathways. Also, signaling pathways implicated in EMT are crucial in autophagy including integrins, WNTs, NF-kB, and TGF-β signaling pathways [123] . In CCA, EMT leads to immunosuppression through SNAIL expression [124] , and is critical for invasiveness and metastasis induced by TGF-β1/SNAIL activation [125] . Autophagy inhibition with CQ reduced invasive capacity under starvation and in TGF-B1 induced CCA cell invasion [126] , further exposing EMT and autophagy relation in CCA.
Beclin1 plays a relevant role in linking autophagy, apoptosis and differentiation and its inactivation and consequent deficiency in autophagy was correlated with malignant transformation [49, 127, 128] . Moreover, several studies have shown the significance of Beclin1 in iCCA [27,28] and eCCA [28] , revealing its prognostic value for CCA. Beclin1 was found markedly expressed in iCCA samples compared with normal bile duct epithelium [27] , and low Beclin1 expression was significantly associated with lymph node metastasis, worse overall survival and less disease-free survival [27, 28] . Moreover, in a lymph node negative CCA subgroup, Beclin1 was higher than in the lymph node positive subset, suggesting that Beclin1 inactivation and therefore impaired autophagy, might promote malignant phenotypes. Interestingly, a stratified survival analysis in patients with Beclin1 low expression, iCCA patients showed a worse overall survival and progression-free survival than eCCA [28] , which may indicate a higher implication of autophagy in iCCA subgroup of patients. Nevertheless, low Beclin1 levels show correlation with poor prognosis in both subtypes [28] . In this line, Ambra1, a positive regulator of Beclin1 dependent program of autophagy, positively correlated with SNAIL expression, in accordance with the impairment of TGF-β1/SNAIL induced EMT by autophagy inhibition [126] . But, in contrast to Beclin1, Ambra1 high expression was associated with lymph node metastasis and poor survival [126] . Other potential therapeutic target associated with autophagic flux in CCA is FOXO1. FOXO1 expression and transcriptional activity are involved in promoting cellular autophagy, and the interaction of acetylated FOXO1 with ATG7 regulates basal and starvation-induced autophagy in CCA cells [30] . Cytoplasmic accumulation of FOXO1 is associated with increased proliferation in cholangiocytes [129] and pharmacological inhibition of acetylated FOXO1, which results in autophagy inhibition, leads to apoptosis induction and reduced viability of CCA cells [30] . Epigenetic alterations are frequent in CCA, such as miR-124, which was found significantly downregulated in the tumor tissue of patients and in CCA cell lines and its administration in vitro induced cytotoxic autophagy in CCA cells [29] , supporting a pro-tumoral role of epigenomic-mediated inhibition of autophagy.
In another recent study, Chen and colleagues demonstrated for the first time that LC3B is an independent biomarker for overall survival and progression-free survival in iCCA patients, and that high LC3B staining significantly associates with poor tumor differentiation, TNM stage, early relapse and bad long term survival. Based on nomograms, they stratified iCCA patients and generate therapeutic strategy after hepatectomy, demonstrating that nomograms based on autophagy markers can be considered as effective models to predict postoperative survival of iCCA patients [31] . In a very interesting study published in 2019, Atg7 was found to be a causative genetic risk factor for CCA development in a family with high incidence of pCCA, identifying a germline mutation associated with CCA development [33] . This genetic variant resulted in the accumulation of p62, indicative of impaired autophagy in the tumors of carriers compared with non-carrier tumors, confirming autophagy pathway perturbation as a novel cancer driver mechanism in human tumorigenesis and in correlating with detection of elevated autophagy related genes in BilIN [105] .
Assembling the pieces of this great puzzle will be necessary to precisely define the role of autophagy in CCA development, its value as prognostic and predictive biomarkers and how its modulation can offer therapeutic benefits for patients that are limited to chemotherapy regime and exhibit limited efficacy.
Clinical development of autophagy modulators in Cholangiocarcinoma
Multiple clinical trials are currently ongoing testing the efficacy of different anticancer drugs on CCA patients administered alone or in combination. A search for phase II and II trials was operated on clinicaltrial.gov (data of entry 2020-01-15) combining terms such as cholangiocarcinoma, autophagy, mTOR, AKT, PI3K, chloroquine and hydroxychloroquine, obtaining a limited set of studies. Two different trials are exploring the inhibition of autophagy in CCA using CQ (NCT02496741-completed; [130] and hydroxychloroquine (HCQ) (NCT03377179-recruiting). The study involving CQ explores safety, recommended phase 2 dose and efficacy of metformin and CQ combinatory treatment in IDH1/2 mutated solid tumors, alteration found in around 20% of iCCA patients. This could seem contradictory given the fact that metformin, an approved anti-diabetic drug, is considered to act by inducing AMPK-mediated autophagy, although its mechanism of action is still far from being completely understood. The study using HCQ, combines this autophagy inhibitor with ABC294640 (Opaganib), a first-in-class sphingosine kinase-2 (SK2) selective inhibitor. ABC294640 was proven to induce protective autophagy in cancer [131] , and this study relies on the HCQ-mediated potentiation of ABC294640 anti-cancer activity by inhibiting ABC294640-mediated protective autophagy in CCA.
When looking at mTOR inhibitors as autophagy inducers in CCA, preclinical evaluation of everolimus (RAD001) showed a reduction in cell proliferation with increased apoptosis and decreased invasion [132], although no reference to autophagy is clearly shown in spite of the association of PI3K/AKT/mTOR signaling pathway with CCA metastasis [133] . PI3K/AKT/mTOR inhibitors in clinical development for CCA include mTOR, PI3K and AKT inhibitors administered alone or in combination with chemotherapy. Among mTOR inhibitors, Everolimus is administered as monotherapy (NCT01525719-unknown and NCT00973713-unknown), in combination with gemcitabine and oxaliplatin (NCT02836847-recruiting) and with FOLFIRINOX (NCT03768375-recruiting) and sorafenib is administered alone (NCT00238212-completed), in combination with gemcitabine and cisplatin (NCT00919061-completed), with gemcitabine and oxaliplatin (NCT00955721-terminated and NCT02836847-recruiting), with erlotinib (EGFR inhibitor)( NCT01093222-completed) and with FOLFIRINOX (NCT03768375-recruiting). Two studies using MK-2206 AKT inhibitor were found administered as monotherapy (NCT01859182-terminated and NCT01425879-completed) and one with BKM120 PI3K inhibitor as monotherapy (NCT01501604-terminated).
Current clinical evaluation of autophagy modulators is still missing, probably due to the lack of knowledge about the mechanism that could lead to a synergistic effect. Only CQ and HCQ are been clinically evaluated and results from these trials, specially HCQ combination with ABC294640, will be of a great interest to obtain initial conclusions of the therapeutic potential of inhibiting autophagy to increase the efficacy of protective autophagy inducing anti-cancer drugs. Nevertheless, further research is needed to try to accurate patient selection in order to increase efficacy.
Autophagy modulators in Cholangiocarcinoma

Autophagy inhibitors
Due to the dual role of autophagy in cancer cells, its modulation either by activation or by inhibition has emerged as a promising therapeutic strategy for cancer treatment. Within the strategies to inhibit autophagy in cancer, several compounds target different steps of the autophagic process such as ULK inhibitors, pan PI3K inhibitors, VPS34 (PI3KC3) complex inhibitors, ATG inhibitors, autophagosome formation inhibition and lysosome Inhibitors [23-25]. In CCA, several publications show the anticancer efficacy of autophagy inhibitors using different approaches. Three studies reported CQ efficacy on CCA cells, an antimalaria drug that inhibits last step of autophagy blocking autophagosome fusion with lysosomes [134-136]. GNS561 is a lysosomotropic small molecule that also blocks fusion of autophagosomes to lysosomes by altering the acidic pH of lysosomes [137] . Several natural compounds are under evaluation in CCA pre-clinical models. Salinomycin (naturally occurring polyether antibiotic [138]), capsaicin (major pungent component of chili pepper [139] ), oblongifolin C (natural small molecule extracted from Garcinia yunnanensis Hu [140] ) and resveratrol (natural phenol, phytoalexin, produced by plants against infections [30]) have shown anticancer efficacy on CCA models by different mechanism, inhibiting autophagosome fusion to lysosomes, promoting mTOR activation and blocking ATG7 activation respectively. Two class III PI3K inhibitors that block initiation of autophagy (3-MA and wortmannin [106]) and Mdivi1 (selective Drp-1 inhibitor [141]) that interferes with mitochondrial activity, have also shown efficacy on CCA.
Hou and colleagues published in 2011 that CCA clinical samples showed higher autophagic vacuole content and increased expression of Beclin1 and Atg5 compared with normal cholangiocytes. Interestingly, they found induction of autophagy in human CCA cell lines under starvation and during tumor formation in xenograft models, suggesting a potential role of autophagy in CCA tumorigenesis and the therapeutic potential of its inhibition. In correlation with this, genetic beclin1 depletion or pharmacological inhibition of autophagy by inhibiting PI3K-Beclin1 complex with 3-MA (3 methyl adenine) and wortmannin hampered proliferation and increased apoptosis during nutrient starvation, sensitizing iCCA cells to chemotherapeutic agent-induced cell death in vitro and in vivo accompanied by a decrease in ATG5 and Beclin1 mRNA levels [106].
Among natural compounds that inhibit autophagy in CCA, capsaicin is the only one that induce autophagy inhibition through mTOR activation. Capsaicin interferes with NF-kB and AP-1 signaling, resulting in negative regulation of cell survival, adhesion, inflammation, differentiation and growth, and although it showed induction of autophagy in melanoma [142], it inhibits autophagy in CCA by activating PI3K/AKT/mTOR pathway, increasing sensitivity of CCA cells to 5-FU [139] . Zang and colleagues reported in 2016 the use of oblongifolin C as an autophagy inhibitor that blocks the autophagosome fusion to lysosomes and promotes mitochondrial dysfunction (MyD), leading to apoptosis induction [140] . Moreover, pharmacologically enhancement of autophagy impaired oblongifolin C effects and treatment with 3-MA potentiated its anticancer effects, reinforcing the implication of the inhibition, although much research is needed to fully understand its precise mechanism of action. Salinomycin is another natural compound which mechanism of action is still unclear, but has been reported to have anticancer activity in CCA by inhibiting autophagy. This antibiotic interferes with Wnt signaling, inhibiting autophagic flux, which leads to the accumulation of dysfunctional mitochondria and increased generation of ROS, suggesting it can affect the fusion of autophagosomes with lysosomes in a similar way to CQ [138] . Moreover, salinomycin inhibited in vivo tumor growth in CCA cell with KRAS mutated and depletion of p53, in correlation with the potential use of this strategy to treat KRAS addicted tumors. Resveratrol, which has been shown to induce autophagy-mediated cell death in leukemia and gastric cancer cells CQ is most widely autophagy inhibitor used in cancer, and currently the only autophagy modulator (except from PI3K/AKT/mTOR inhibitors) under clinical evaluation for CCA. In CCA models, CQ attenuates invasive activity of CCA cells under starvation conditions, reducing TGF-b1-induced CCA cell invasion [134] and sensitizing resistant CCA cell to cisplatin [135] . CQ acts inducing sustained ER stress by blocking the binding of autophagosomes to lysosomes altering acidic environment of lysosomes, resulting in accumulation of a large number of degraded proteins in the cytoplasm, inducing ER stress. This sustained ER stress activates CHOP, which finally induces the activation of multiple death signaling pathways in CCA, including caspase 3 and 8, cleaved PARP and Bcl-2 family proteins Bax and Bak [136] .
Activation of autophagy as a resistance mechanism in response to chemotherapy has been widely described for many different types of cancers, including CCA [60-63]. A wide variety of anticancer compounds induce autophagy in CCA, making it necessary to discern whether it is a protective autophagy promoted by cancer cells as an adaptive mechanism, therefore inhibition of autophagy leads to a potentiation of their cytotoxic effects, or if on the contrary, mediates drug mechanism of cancer cell death induction. Several compounds that show anticancer efficacy on CCA cells such as norcantharidin [145], compound C [146], vorinostat [147] or cisplatin [106], [141] induce the activation of protective autophagy in CCA cells, and pharmacological inhibition of autophagic process enhances these drugs anti-cancer capacity, accelerating apoptosis and sensitizing cell to chemotherapy. The combination of these drugs with autophagy inhibitors offers an attractive therapeutic strategy. Following this rationale, currently recruiting clinical trial combining HCQ with SK2 selective inhibitor ABC294640 in CCA patients attacks cancer cells inhibiting ABC294640-induced protective autophagy, with the aim to increase efficacy in these patients. This is a very promising strategy to apply to other combination that has already shown pre-clinical efficacy.
Autophagy activators
There are several strategies currently under evaluation to induce autophagy mediated cell death in cancer, including mTOR inhibitors, BH3 (Bcl-2 homology 3) mimetics which promote the liberation of Beclin-1 from Bcl2 and Bcl-XL inhibition [148], cannabinoids which induce an exacerbated ER stress on cancer cells ultimately leading to CHOP-mediated apoptotic cell death [149] , HDAC inhibitors which act through the epigenetic modulation of autophagy [22, 150] , and natural compounds extracted from plants, herbs or insects [22, 150] .
Three natural compounds have been recently described to induce CCA cell death implicating the activation of autophagy as mediator of their cytotoxic effects, such as piperlongumine (small molecule extracted from Piper longum plant [151]), pterostilbene (active constituent of blueberries [152]), pristimerin (triperpenoid isolated from Maytenus heterophylla [153] ) and dihydroartemisinin (active compound found in Artemisia annua [154] . Although it has been proven that autophagy induction is necessary for their mechanism of action, the specific molecular mechanisms governing their autophagy modulation abilities are not fully understood yet. Piperlongumine induced apoptosis [155] and autophagy [151] in CCA cells through the production of ROS, induction of ER stress and activation of JNK-ERK signaling pathway [151] . Similar to piperlongumine, dihydroartemisinin is an antimalaria drug that induces ROS mediated ER stress through DAPK activation, promoting the disruption of Beclin1-Bcl-2 complex and inducing autophagy-mediated CCA cell death, therefore activating initiation of autophagy. Importantly, its cytotoxic effects were cancer cell-specific, since only slight toxicity was observed on immortalized cholangiocytes. Beclin1 activation is crucial for dihydroartemisinin action since its genetic depletion or its pharmacologically mediated degradation inhibited autophagy activation and partially protect CCA cells from dihydroartemisinin treatment [154] . Another drug that promotes Beclin1 activation is pristimerin, which inhibited CCA cell growth in vitro and in vivo decreasing apoptosis-related proteins Bcl-2, Bcl-XL and procaspase-3, similarly to the effect of BH3 mimetics, suggesting pristimerin promotes Beclin1 activation and initiation of autophagy. Interestingly, this compound showed higher efficacy Decitabine can potentially modulate response of cancer cells to chemotherapy and radiotherapy [159] and induces apoptosis and autophagy-dependent caspase-independent CCA cell death in vitro, reducing tumor growth in vivo [156] . While pristimerin showed more efficacy on iCCA versus eCCA cells, decitabine showed was different efficacy among two different eCCA cell lines, suggesting the induction of autophagy with this compound may be related to cell-specific characteristics rather than to the morphologic origin of CCA [156] . Another epigenetic factor, miR-124, induces tumor suppressive effect in CCA by inducing autophagic flux, leading to autophagy-related cell death in a mechanism involving EZH2-STAT3 signaling axis. Silencing of Beclin1 or ATG5 abrogated the effects and overexpression of miR-124 in xenograft models resulted in autophagy-mediated suppression of tumorigenicity through STAT3 activation, Bcl-2 downregulation and Beclin1 expression, which indicates it acts at the initiation of autophagy. Moreover, miR-124 was downregulated in human CCA samples compared with non-tumor tissue [29] . Another approach to induce autophagy in CCA cells has been through the activation of LKB1-AMPK pathway leading to mTOR inhibition by phenformin. Hu and colleagues showed that phenformin inhibits complex 1 of mitochondria, increasing intracellular AMP and inducing the activation of LKB1-AMPK axis, leading to mTOR inhibition. As a consequence, apoptosis and autophagy are increased, along with increase in ATG7, ATG5 and Beclin1 levels, therefore acting on mTOR-mediated ULK1 complex activation during initiation of autophagy. The last published report precisely determined the mechanism of action of ABTL0812, which induces cytotoxic autophagy on CCA cells by inducing robust and sustained ER stress [158], [160] along with TRIB3-mediated Akt/mTOR axis inhibition [161] . Similar to dihydroartemisinin, at ABTL0812 concentrations that result lethal for CCA cells in vitro, immortalized cholangiocytes remain alive suggesting the safety of this type of anti-cancer treatments. Promotion of autophagy in response to cell stress conditions such as lack of growth factors or hypoxia activates autophagy via mTORC1 inhibition [162] . Additionally, other types of cell stresses promote autophagy through the UPR response and mediated by PERK, IRE1α or CAMKK2 protein [163] . PERK activation directly activates ATG12-ATG5-ATG16L complex which induces PERK-ATF4-CHOP pathway activation and TRIB3 (Tribbles homolog 3) expression, a pseudokinase that acts as an endogenous negative regulator of AKT/mTOR axis [158, 164, 165] . IRE1α promotes Beclin1 liberation from Bcl2 and PI3K-Beclin1 complex activation [163] . This is the case for some drugs such as tetrahydrocannabinol (THC), which exert its antitumoral action by inducing ER stress-mediated apoptotic cell death [149, 166, 167] and has shown anti-cancer efficacy in CCA [168] . ABTL0812 is the autophagy inductor currently being evaluated in CCA models with most complete description of its mechanism of action, and it already showed preliminary clinical efficacy on a CCA patient derived from a phase I trial in patients with solid tumors [160, 169] . In xenograft models, ABTL0812 potentiated gemcitabine plus cisplatin anticancer efficacy by upregulating TRIB3 and CHOP levels, two markers that have been validated for the first time as surrogate pharmacodynamic biomarkers in endometrial and lung cancer patients [158, 160, 170, 171] . This novel strategy to induce ER stress mediated cytotoxic autophagy relies on the fact that cancer cells have evolved to use the UPR to survive the ER stress induced by the hostile conditions of tumor microenvironment (hypoxia, low glucose, intracellular acidification, etc.), exhibiting higher ER stress basal levels [172] ). The induction of ER stress in cancer cells is a common mechanism of natural compounds activators of autophagy, and can result in an overpass of the cytoprotective effect of the UPR, leading to activation of the pro-apoptotic arm (CHOP) and to cell death. On the contrary, non-tumoral cells show negligible levels of ER stress and therefore possess a broader margin to resist stress-induced cytotoxicity [173], correlating with lower cytotoxicity on immortalized cholangiocytes observed for ABTL0812 and dihydroartemisinin. Autophagy modulators in pre-clinical studies in CCA. * Uncomplete mechanism of action
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DISCUSSION AND FUTURE PERSPECTIVES
Autophagy is a tightly orchestrated multi-step catabolic process in which misfolded, aggregated or mutant proteins and damaged organelles are sequestered in double membrane vesicles called autophagosomes, that ultimately leads to the degradation of the sequestered components upon fusion with lysosomes. Autophagy is generally a pro-survival mechanism, which allows cells to recover homeostasis in stressed cells by controlling energy and nutrient balance [17, 18] . The presence of multiple checkpoints within the autophagic process increases the possibilities to disturb autophagy, leading to different human diseases including cancer, although it also offers multiple target points for therapeutic approaches [19] . Autophagy may act as tumor suppressor at the early stages of cancer development, clearing the accumulation of impaired macromolecules and organelles that cause DNA damage and chromatin instability, key factors in the accumulation of oncogenic mutations [43, 44] . On the contrary, deficiencies in autophagy lead to the accumulation of p62 aggregates, defective mitochondria, poorly folded proteins and increased intracellular ROS, promoting malignant transformation [43, 51, 52] .
In CCA, numerous evidences strongly suggest a deregulated autophagy at the initial steps of cholangiocarcinogenesis, appearing higher levels of LC3 and p62 in precursor BilIN lesions compared with normal biliary ducts [32] . In this line, IL-6 mediated chronic inflammation in biliary cells leads to cholangiocarcinogenic transformation [45] [46] [47] . The role of autophagy and inflammation Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 3 February 2020 doi:10.20944/preprints202002.0015.v1
is widely described in the context of cancer development. It has been demonstrated that continuous IL-6 secretion mediated by STAT3 inhibits autophagy, contributing to arsenic carcinogenesis in lung cells during carcinogenesis [80] and reinforcing the idea of impaired autophagy during CCA establishment. Moreover, Atg7 was found to be a causative genetic risk factor for CCA development in a family with high incidence of pCCA and higher levels of p62 were found in tumors of the carriers compared with non-carriers [33] . Autophagy can also act promoting tumor growth on stablished tumors serving as an adaptive and pro-survival mechanism against the extreme tumor microenvironment conditions such as lack of oxygen, limited nutrients and high metabolic rate [53] [54] [55] . According to this data, RAS-mutated cells are addicted to autophagy by maintaining oxidative metabolism and glycolysis, underpinning growth, survival, invasion and metastasis [58, 59] . RAS appears frequently mutated in CCA, with higher prevalence in dCCA [72], suggesting these cells could also have high dependence on autophagy for survival, and similar to other KRAS-driven cancers autophagy inhibition could offer an attractive therapeutic option. Autophagy has been directly related with higher invasive capacity in CCA mediated by TGF-β/SNAIL-induced EMT [125] and inhibition of autophagy impaired invasiveness in vitro mediated by TGF-β/SNAIL-induced EMT, theorizing that lower levels of autophagy seem to have a positive impact on reducing the metastatic potential of CCA cells [126] . Moreover, autophagy has also been associated as a protective mechanism to induce resistance to various therapies and promote chemoresistance and tumor survival [60-63]. A wide variety of anticancer compounds induce protective autophagy in CCA [145-147] including chemotherapy [106,141] and the inhibition of this protective mechanism with specific inhibitors accelerated apoptosis and sensitized cells to chemotherapy. Furthermore, Beclin1 was found markedly expressed in iCCA samples compared with normal bile duct epithelium [27] , correlating with increased autophagy on established tumors, which may be used by CCA cells as tumor promoter mechanism. Beclin1 has been defined as tumor suppressor and is a critical factor in autophagy initiation, directly interacting with pro-survival and pro-death factors, thus being involved in cell fate decision making [44, 49, 174] . Its correlation with poor prognosis in CCA [27,28] makes beclin1 an interesting prognostic factor in CCA, potentially stratifying subpopulations of patients with worse expectations and those who could benefit from autophagy inhibition treatment in combination with standard chemotherapy to increase efficacy and overall survival.
Autophagy modulation has emerged as a promising therapeutic strategy to treat different types of cancers [22] [23] [24] 62] . Autophagy inhibition using CQ in CCA could offer therapeutic advantages in combinatory treatments with anti-cancer drugs that induce protective autophagy such as norcantharidin [145], compound C [146], vorinostat [147] or cisplatin [106, 141] , which have shown efficacy on pre-clinical models of CCA. Multiple combinations could be used to attack CCA cells using combined strategies. For example, chemotherapy as the standard treatment can be combined with CQ or HCQ to avoid development of resistance in KRAS mutated CCA or with targeted therapies such as IDH1, FGFR or ERBB inhibitors for IDH, FGFR or ERBB mutant CCAs. These combinations could offer an interesting strategy to increase therapeutic outcomes, although pre-clinical research should be carried out to define whether these combinations are suitable and to select specific CCA subpopulations of patients. Among all compounds that show efficacy against CCA by inhibiting autophagy, class III PI3K inhibitors could open new therapeutic avenues since their specificity for this type of PI3K and the inhibition of initial steps of autophagy seems an effective way to block this process. Further combination with chemotherapy and other drugs in different types of CCA would be of a great interest to implement these compounds in clinics. Other inhibitors such as natural compounds salinomycin, oblongifolin C, MdIvi1 or resveratrol will need further research to uncover its precise mechanism of action.
Induction of autophagy appears as other interesting approach to treat CCA. Different natural compounds such as piperlongumine, pterostilbene, pristimerin and dihydroartemisinin induce autophagy dependent CCA cell death, although their molecular mechanism of action is still unclear. The widely described epigenomic alterations in CCA and their correlation with poor prognosis and the epigenetic induction of autophagy in CCA by decitabine and miR-124 underscore the regulatory Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 3 February 2020 doi:10.20944/preprints202002.0015.v1
role of epigenomics in controlling of autophagy [108], although further research is needed to fully understand these relationships to be used in clinics. The induction of ER stress mediated cytotoxic autophagy by increasing intracellular dihydroceramides (Dh-Cer) content has been proposed as a safe and efficient way to induce autophagy mediated apoptosis in cancer cells. Resveratrol [144] , which in CCA acts inhibiting autophagy, and THC [175] induce an increase in Dh-Cer in cancer cells by inhibiting dihydroceramide desaturase (Des-1), which is responsible for ER stress mediated autophagy promotion. Similarly, ABTL0812 induces impairment of Des-1 activity, resulting in the accumulation of Dh-Cer and activation of UPR response, which in combination with TRIB3-mediated AKT/mTOR axis inhibition, triggers cytotoxic autophagy in CCA cells [158, 160] . Interestingly, Des1 expression was found to be upregulated in CCA cell lines compared with their non-tumor counterparts NHC3 cells [158] , which could be one of the reasons for the selectivity observed for cancer cells to ABTL0812. Same selectivity is observed for dihydroartemisinin, thus evaluate Des1 activity and Dh-Cer content in dihydroartemisinin treated CCA cells, as well as exploring Des1 expression among clinical samples, could greatly help design novel therapeutic strategies and stratify patients for clinical assessment. Analogous to autophagy inhibitors, multiple combinatory treatments including autophagy promoter drugs arises as a potentially successful strategy. ABTL0812 has already shown potentiation of chemotherapy in lung [171] and endometrial cancer [170] . In mesothelioma [176] and multiple myeloma [177], ER stress mediated induction of cytotoxic autophagy induces the release of immunogenic signals that make tumors more immunogenic and targetable for immune system. The induction of immunogenic cell death mediated by autophagy has been described for different drugs, including chemotherapy, being the basis for its combination with immunotherapies such as immune checkpoint inhibitors [178] . Pembrolizumab (anti-PD1) was tested in advanced biliary tract cancer with modest efficacy response rates [179], therefore combining ER stress mediated inductors of autophagy with chemotherapy to increase tumor immunogenicity and with anti-PD1 treatment could significantly increase the therapeutic ratio.
In summary, autophagy modulation arises as a promising strategy for combinatory treatments that aim to attack tumors summing different strategies. Coming all the puzzle pieces together to understand the specific molecular mechanisms to design novel treatment strategies will be a hard assignment and should be a priority for researchers. To determine when inhibition or activation of autophagy could offer better results and identify specific cellular conditions on cancer cells that help identify sub-populations of patients that would respond better to each specific treatment, will offer alternative therapeutic strategies for patients suffering from this devastating disease.
